Abstract
Colon cancer is one of the most prevalent cancers globally, especially in the older age group. A large number of older patients undergoing surgery for colon cancer suffer from postoperative cognitive dysfunction (POCD). The trial by Bu et al demonstrated that dexmedetomidine (Dex) significantly reduced the incidence of POCD compared to placebo in individuals undergoing colon cancer surgery. Additionally, better cerebral oxygenation and lower cerebral injury markers were reported with the use of Dex. The trial has some limitations, such as a single-center design and a smaller sample size, and further studies with larger patient populations and robust multi-center designs are warranted to establish these findings.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
